https://www.selleckchem.com/pr....oducts/shin1-rz-2994
Taken together, this is the first study to demonstrate that combination treatment with Itolizumab and insulin is safe in humans and does not affect the residual function of beta cells up to 52 weeks. The findings from our study show preliminary evidence that high doses of Itolizumab could potentially arrest the loss of beta cell function in the long term. Further studies with a longer follow-up and larger numbers of patients are envisaged to assess the effect with high dose Itolizumab.Autosomal aneuploidies are the most frequently
Curtir
Comentario
Compartilhar
